Search Results

By Sameer A. Mahesh, MD  / January 15, 2014

Role of Autologous Stem Cell Transplant in High-Risk NHL

As described in the December 15 issue of The ASCO Post, Stiff and colleagues treated patients with high-intermediate– or high-risk diffuse, aggressive non-Hodgkin lymphoma with five cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP plus rituximab (Rituxan)....